NASD · Healthcare · Drug Manufacturers - General · USA
Gilead Sciences Inc is a large cap company (market value between $10 billion and $200 billion) in the Drug Manufacturers - General industry.
Gilead Sciences is a biopharmaceutical company creating treatments for HIV, viral hepatitis, COVID-19 and cancer. Its therapeutic portfolio covers virology, oncology and related areas, distributed globally through wholesalers, resellers and business collaborators. The company also generates revenue from intellectual property royalties and licensing deals.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Gilead Sciences Inc stock.
Overvalued: intrinsic value $119.78 per share, market price $153.07, margin of safety -27.8% (as of 2026-10-19).
Discounting its cash flows at 7.5% (average of 2 methods) values the shares at $119.78; the price of $153.07 is 28% above that value, and 81% of that value comes from beyond year five.
Leak Score: 64/100 on 11 of 12 signals (Faint Leak).
17 more funds hold it; the full list is part of the paid plan.
All 21 Drug Manufacturers - General stocks
4 more in this industry show a wider margin of safety.
GILD is overvalued (as of the 2026-10-19 close). Discounting its cash flows at 7.5% (average of 2 methods) values the shares at $119.78; the price of $153.07 is 28% above that value, and 81% of that value comes from beyond year five.
$119.78 per share (as of the 2026-10-19 close), against a market price of $153.07. That is a margin of safety of -27.8%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
The price asks for more growth than the company has delivered. It needs the future to beat the past. Yearly sales growth the price needs: 12.2%. Yearly sales growth it has sustained: 2.4%.
64 out of 100, which we rate "Faint Leak", on 11 of 12 value investing signals.